V3V Stock Overview
VITA 34 AG engages in the collection, processing, and cryopreservation of stem cells from umbilical cord blood and tissue in Germany, Poland, Portugal, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
VITA 34 AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €5.00 |
| 52 Week High | €7.30 |
| 52 Week Low | €3.69 |
| Beta | 0.60 |
| 1 Month Change | 15.21% |
| 3 Month Change | -3.85% |
| 1 Year Change | -28.57% |
| 3 Year Change | -70.41% |
| 5 Year Change | -64.79% |
| Change since IPO | -61.00% |
Recent News & Updates
Why We're Not Concerned About VITA 34 AG's (ETR:V3V) Share Price
Apr 04
Revenues Tell The Story For VITA 34 AG (ETR:V3V) As Its Stock Soars 26%
Dec 24Recent updates
Why We're Not Concerned About VITA 34 AG's (ETR:V3V) Share Price
Apr 04Revenues Tell The Story For VITA 34 AG (ETR:V3V) As Its Stock Soars 26%
Dec 24Is VITA 34 (ETR:V3V) Using Too Much Debt?
Nov 23Is VITA 34 (ETR:V3V) Using Debt In A Risky Way?
Jul 15Is VITA 34 (ETR:V3V) Using Debt In A Risky Way?
Feb 17Is It Too Late To Consider Buying VITA 34 AG (ETR:V3V)?
Apr 08VITA 34 AG's (ETR:V3V) CEO Compensation Looks Acceptable To Us And Here's Why
Dec 07Is It Too Late To Consider Buying VITA 34 AG (ETR:V3V)?
May 12Earnings Miss: VITA 34 AG Missed EPS By 29% And Analysts Are Revising Their Forecasts
Apr 03VITA 34 AG's (ETR:V3V) Intrinsic Value Is Potentially 56% Above Its Share Price
Mar 25Should You Be Adding VITA 34 (ETR:V3V) To Your Watchlist Today?
Mar 10Here's Why VITA 34 (ETR:V3V) Can Manage Its Debt Responsibly
Feb 22Is It Too Late To Consider Buying VITA 34 AG (ETR:V3V)?
Feb 05Can Mixed Financials Have A Negative Impact on VITA 34 AG's 's (ETR:V3V) Current Price Momentum?
Jan 18Did You Participate In Any Of VITA 34's (ETR:V3V) Fantastic 201% Return ?
Jan 02How Is VITA 34's (ETR:V3V) CEO Compensated?
Dec 18Should You Be Adding VITA 34 (ETR:V3V) To Your Watchlist Today?
Dec 01
Shareholder Returns
| V3V | DE Healthcare | DE Market | |
|---|---|---|---|
| 7D | 11.1% | 5.4% | 1.7% |
| 1Y | -28.6% | 0.6% | 2.3% |
Return vs Industry: V3V underperformed the German Healthcare industry which returned 1.9% over the past year.
Return vs Market: V3V underperformed the German Market which returned 2.2% over the past year.
Price Volatility
| V3V volatility | |
|---|---|
| V3V Average Weekly Movement | 7.3% |
| Healthcare Industry Average Movement | 6.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: V3V has not had significant price volatility in the past 3 months.
Volatility Over Time: V3V's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 815 | Jakub Baran | www.vita34.de |
VITA 34 AG engages in the collection, processing, and cryopreservation of stem cells from umbilical cord blood and tissue in Germany, Poland, Portugal, and internationally. It also develops products and drugs based on cells, tissues, and blood for medical applications; and produces viral vectors and CAR-T cells. The company manufactures advanced therapy medicinal products for third parties.
VITA 34 AG Fundamentals Summary
| V3V fundamental statistics | |
|---|---|
| Market cap | €87.16m |
| Earnings (TTM) | -€24.83m |
| Revenue (TTM) | €74.86m |
1.2x
P/S Ratio-3.5x
P/E RatioIs V3V overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| V3V income statement (TTM) | |
|---|---|
| Revenue | €74.86m |
| Cost of Revenue | €49.00m |
| Gross Profit | €25.86m |
| Other Expenses | €50.69m |
| Earnings | -€24.83m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
Apr 30, 2024
| Earnings per share (EPS) | -1.42 |
| Gross Margin | 34.54% |
| Net Profit Margin | -33.18% |
| Debt/Equity Ratio | 105.1% |
How did V3V perform over the long term?
See historical performance and comparison